Elemene Liposomes with Chemotherapy in Advanced or Recurrent Endometrial Cancer
Tests elemene liposomes added to chemotherapy in adults with advanced or recurrent endometrial cancer.
Plain-language title generated from the registry record
Registry title: Elemene Liposomes in Endometrial Cancer
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with advanced or recurrent endometrial cancer who will receive carboplatin and paclitaxel chemotherapy, with or without Elemene.
- Age
- 18 to 80 years
- Sex
- Women only
- Disease stage
- Endometrial cancer confirmed under the microscope (for example endometrioid, serous, clear cell, mixed, undifferentiated carcinoma, carcinosarcoma). Either untreated FIGO 2009 stage III-IV disease, or recurrent disease with no limit on the number of recurrences. Non-epithelial tumors such as mesenchymal, neuroectodermal and germ cell tumors are not included.
- Earlier treatment
- Treatment-naïve for stage III-IV disease. No chemotherapy, anti-tumor immunotherapy or radiotherapy within 6 months before randomization.
Main reasons for not taking part
- Another primary cancer within the last 3 years
- Taking part in another interventional clinical study at the same time
- Uncontrolled other illnesses (heart, brain, blood, liver or kidney problems) or drug or alcohol abuse
- Severe complications after surgery that have not fully resolved
- Known allergy to the study drugs (Elemene Liposomes Injection, Elemene Emulsion Oral Solution)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07738315, who can take part
Where in China
- Women's hospital school of medicine Zhejiang UniversityHangzhou, ChinaContact: Yang LiNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Women's Hospital School Of Medicine Zhejiang University
- Trial code
- NCT07738315
- Record updated
- 31 July 2026
- Original description
The goal of this clinical trial is to learn if Elemene Liposomes, combined with carboplatin and paclitaxel (TC) chemotherapy can improve prognosis in patients with advanced or recurrent endometrial cancer. The main question it aims to answer is:Read full original descriptionShow less
A Prospective, Multicenter, Randomized Controlled Trial of Elemene Liposomes Combined With TC Chemotherapy in Advanced or Recurrent Endometrial Cancer
The goal of this clinical trial is to learn if Elemene Liposomes, combined with carboplatin and paclitaxel (TC) chemotherapy can improve prognosis in patients with advanced or recurrent endometrial cancer. The main question it aims to answer is:
Does adding Elemene Liposomes to TC chemotherapy can delay disease recurrence time in patients with advanced or recurrent endometrial carcinoma.
Researchers will compare Elemene Liposomes +TC chemotherapy to TC chemotherapy alone to see if Elemene Liposomes, combined with carboplatin and paclitaxel (TC) chemotherapy can improve prognosis in patients with advanced or recurrent endometrial cancer.
Participants will:
* Receive TC Chemotherapy every 21 days, for a total of 6 cycles. * Take intravenous infusion of Elemene liposome injection every day from day 1 to day 7 of cycle 1 and 2, and take oral Elemene emulsion twice every day, from day 1 to day 14 of cycles 3 to cycle 6. (no intravenous or oral Elemene will be given in comparison group) * Visit the clinic for checkups and tests once every 21 days during treatment and every 3 to 12 months after the treatment is completed.
Inclusion: Histopathologically confirmed endometrial malignancy via surgery or biopsy, including endometrioid carcinoma, serous adenocarcinoma, clear cell carcinoma, mixed epithelial carcinoma, dedifferentiated/undifferentiated carcinoma, carcinosarcoma, etc. Non-epithelial tumors such as mesenchymal tumors, neuroectodermal tumors and germ cell tumors are excluded; Treatment-naïve patients with FIGO 2009 stage III-IV disease, or patients with clinically diagnosed recurrent endometrial malignancy (no restriction on the number of recurrences, and no restriction on whether reoperation was performed after recurrence). Patients must not have received chemotherapy, anti-tumor immunotherapy or radiotherapy within 6 months before randomization; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to randomization; Adequate organ function defined as: white blood cell count ≥3.5×10⁹/L, absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥80×10⁹/L, serum total bilirubin ≤1.5×upper limit of normal (ULN), transaminases (alanine aminotransferase, aspartate aminotransferase) ≤1.5×ULN, serum creatinine and blood urea nitrogen ≤1.5×ULN OR calculated creatinine clearance ≥30 mL/min. All laboratory tests shall be performed within 7 days prior to randomization. Left ventricular ejection fraction ≥lower limit of normal (50%) as assessed by Doppler echocardiography; Negative serum or urine pregnancy test within 7 days before enrollment, and non-lactating status.
Exclusion: History of other primary malignant tumors within 3 years prior to randomization; Concurrent participation in another clinical study, except for observational, non-interventional clinical studies; Uncontrolled concomitant diseases, including but not limited to cardiac disorders, cerebral diseases, hematological diseases, congenital or postoperative hepatic/renal abnormalities; drug and/or alcohol abuse; Known allergy or contraindications to the study drugs (Elemene Liposomes Injection, Elemene Emulsion Oral Solution); Severe postoperative complications that have not fully resolved.